Global Breast Tomosynthesis Market – Industry Trends and Forecast to 2031

Breast Tomosynthesis Market Analysis and Size

Breast tomosynthesis plays a crucial role in breast cancer screening by offering several advantages over traditional 2D mammography. It provides radiologists with detailed 3D images of the breast tissue, reducing overlapping structures that can obscure abnormalities, particularly in dense breasts. This technology enhances the detection of early-stage cancers and lesions that may not be visible on 2D scans, leading to fewer false positives and fewer unnecessary callbacks for additional testing. As a result, tomosynthesis improves overall diagnostic accuracy and increases the chances of detecting breast cancer at its earliest and most treatable stages, thereby potentially improving patient outcomes.

The global breast tomosynthesis market size was valued at USD 2.61 billion in 2023 and is projected to reach USD 6.99 billion by 2031, with a CAGR of 13.10% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

Breast tomosynthesis, also known as 3D mammography, is an advanced imaging technique used for breast cancer screening and diagnosis. It captures multiple images of the breast from different angles, allowing radiologists to reconstruct a 3D image of the breast tissue. This method provides clearer, more detailed views than traditional 2D mammography, reducing the chances of false positives and improving detection of breast abnormalities, especially in dense breast tissue.

Breast Tomosynthesis Market Dynamics

Drivers                                                                                                        

• Growing Consumer Awareness

As awareness increases about the importance of early detection in breast cancer, individuals become more proactive in seeking advanced screening technologies such as tomosynthesis. This heightened awareness is often fueled by media coverage, educational campaigns, and advocacy efforts promoting the benefits of 3D mammography over traditional methods. Patients and healthcare consumers, particularly those with a family history of breast cancer or other risk factors, are increasingly requesting access to more accurate and reliable breast tomosynthesis screening options. This trend boosts demand for tomosynthesis systems and encourages healthcare providers to invest in these technologies to meet patient expectations and improve diagnostic outcomes.

• Rising Incidence of Breast Cancer

As breast cancer rates increase, there is a heightened need for more accurate and reliable screening methods to detect the disease at its earliest stages. Tomosynthesis offers superior imaging capabilities compared to traditional 2D mammography, enhancing the detection of small tumors and lesions that may be missed by conventional methods. This improved sensitivity reduces false negatives and improves overall diagnostic accuracy, thereby supporting early intervention and better treatment outcomes. The growing awareness of breast cancer and the emphasis on early detection further fuel the adoption of tomosynthesis, making it a crucial technology in the fight against breast cancer.

Opportunities

• Increasing Supportive Regulatory Frameworks

Supportive regulatory frameworks ensures safety, efficacy, and accessibility of these advanced medical technologies. Regulatory agencies worldwide, such as the FDA in the U.S. and CE marking in Europe, provide approvals and clearances that validate the use of tomosynthesis systems for clinical applications. Moreover, regulatory support facilitates reimbursement policies from healthcare payers, making it financially feasible for healthcare facilities to offer tomosynthesis screenings. This regulatory backing thus accelerates market growth by creating a conducive environment for innovation, adoption, and integration into routine clinical practice.

• Expansion of Healthcare Infrastructure

As countries invest in developing and upgrading healthcare facilities, there is an increased capacity and capability to adopt advanced medical technologies such as tomosynthesis. This expansion includes the establishment of new hospitals, clinics, and diagnostic centers equipped with modern imaging equipment. Improved access to healthcare services in both urban and rural areas enhances the reach of breast cancer screening programs utilizing tomosynthesis. Infrastructure development often involves training healthcare professionals on the use of new technologies, fostering greater adoption and integration of tomosynthesis into routine clinical practice.

Restraints/Challenges

• High Cost Of breast Tomosynthesis Machine

High breast tomosynthesis cost are expensive to purchase, install, and maintain, requiring substantial upfront investment from healthcare facilities. The cost burden is further compounded by ongoing expenses for training personnel, upgrading software, and ensuring compliance with regulatory standards. This financial barrier limits adoption rates, especially in healthcare settings with constrained budgets or in regions with lower healthcare expenditure. Additionally, the return on investment timeline for these high-cost systems can be lengthy, deterring some facilities from upgrading or investing in tomosynthesis technology.

• Growing Technological Complexity

The operation and interpretation of tomosynthesis systems require specialized training for radiologists and technicians, which can be time-consuming and costly. This complexity may deter healthcare facilities from adopting the technology, especially in regions with limited access to training programs or skilled personnel. Moreover, integrating tomosynthesis into existing workflow and IT systems can be challenging, leading to potential disruptions and inefficiencies. As a result, the learning curve and initial investment required to implement tomosynthesis may hinder its widespread adoption, particularly in smaller or less advanced healthcare settings.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2022, Whiterabbit launched ACT software in August 2022, designed to automate the analysis of digital breast tomosynthesis images (3D mammograms) for diagnosing breast cancer. This innovation aims to enhance diagnostic accuracy and efficiency by leveraging advanced algorithms for image interpretation
• In May 2022, Therapixel secured EUR 15 million in Series B funding. This investment was intended to bolster the company's commercial expansion efforts in the U.S. It also aimed to further develop their MammoScreen platform, enhancing its capabilities as a reading aid for mammography. The funding underscored investor confidence in Therapixel's technology and growth potential in the medical imaging market
• In January 2021, Hologic expanded its ultrasound portfolio in January 2021 with the introduction of the SuperSonic MACH 20 ultrasound machine. This system integrated advanced features including high-resolution B-mode imaging and ShearWave PLUS elastography in 3D volumes. The innovation was targeted at improving diagnostic accuracy and expanding the applications of ultrasound imaging, particularly in Europe where it was expected to see rapid adoption

Breast Tomosynthesis Market Scope

The market is segmented on the basis of product, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• 2D/3D Combination Systems
• Standalone 3D Systems

End User

• Hospitals
• Diagnostic Centres
• Others

Breast Tomosynthesis Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, product and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.

North America dominates the market due to increasing incidence of breast cancer. This advanced imaging technology allows for clearer and more accurate detection of breast abnormalities, thus improving diagnostic outcomes. Additionally, despite rising healthcare costs, the demand for more effective diagnostic tools is pushing market expansion further. These factors are expected to sustain robust growth in the digital breast tomosynthesis market across North America.

Asia-Pacific is expected for substantial growth in the market due to increasing adoption of advanced medical technologies and rising healthcare expenditure are key drivers. The presence of major players expanding their operations in emerging economies within the region enhances market penetration. Moreover, growing awareness about early detection of breast cancer and improving healthcare infrastructure further contribute to the market's expansion in Asia-Pacific. These dynamics collectively position the region as a pivotal area for the digital breast tomosynthesis market's future growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Breast Tomosynthesis Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Siemens (Germany)
• Hologic, Inc. (MA)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Abbott (U.S.)
• BD (NJ)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Shimadzu Medical (India) pvt. Ltd. (Japan)
• GENERAL ELECTRIC (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Sysmex India Pvt. Ltd. (Japan)
• Hitachi, Ltd. (Japan)
• Canon Inc. (Japan)
• FUJIFILM Holdings Corporation (U.K)

SKU-68233